Objective-Platelets are crucial for hemostasis and are vital regulators of inflammation. Foxp3 is a key transcription factor for T regulatory cell development. Humans with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, x-linked) and the scurfy (Foxp3 sf ) mouse have mutations in the Foxp3 gene that lead to a host of pathologies including autoimmunity and skin diseases. Scurfy mice and some humans with IPEX are also thrombocytopenic. The purpose of this study was to determine whether the absence of functional Foxp3 leads to defects in megakaryocytes and platelets. Methods and Results-We discovered that human and mouse megakaryocytes express Foxp3 mRNA and protein. Using shRNA and Foxp3 sf mice, we demonstrated that Foxp3-deficient mouse and human megakaryocyte progenitors exhibited proliferation defects. Striking platelet abnormalities were observed in both an IPEX patient and Foxp3 sf mice. Impaired platelet spreading and release of TGF-␤ and CD40 ligand (CD40L), and abnormal levels of plasma CD40L were observed in a case of IPEX syndrome. Foxp3 sf mice were thrombocytopenic and had increased platelet volume and altered serum levels of CD40L, TXB 2 , and TGF-␤. Key Words: megakaryocytes Ⅲ platelets Ⅲ Foxp3 Ⅲ IPEX P latelets play vital roles in the normal hemostatic response to injury and are key cellular elements in diseases such as stroke and myocardial infarction. 1 They are also now recognized as contributing to chronic diseases such as type-2 diabetes. 2 Platelets contain mRNAs, pre-mRNAs, and splicing machinery to synthesize proteins. 3 In addition, they release proinflammatory eicosanoids and proteins such as CD40 ligand (CD40L; formally called CD154), a potent cytokine that activates immune cells and structural cells such as endothelial cells. These biological processes make platelets important regulators of the immune system and the inflammatory response. In addition to unwanted platelet activation, loss of platelet function can also lead to morbidity and mortality. Reduced platelet number through autoimmunity, cancer chemotherapy, or ionizing radiation exposure can be fatal.
P latelets play vital roles in the normal hemostatic response to injury and are key cellular elements in diseases such as stroke and myocardial infarction. 1 They are also now recognized as contributing to chronic diseases such as type-2 diabetes. 2 Platelets contain mRNAs, pre-mRNAs, and splicing machinery to synthesize proteins. 3 In addition, they release proinflammatory eicosanoids and proteins such as CD40 ligand (CD40L; formally called CD154), a potent cytokine that activates immune cells and structural cells such as endothelial cells. These biological processes make platelets important regulators of the immune system and the inflammatory response. In addition to unwanted platelet activation, loss of platelet function can also lead to morbidity and mortality. Reduced platelet number through autoimmunity, cancer chemotherapy, or ionizing radiation exposure can be fatal.
Normal megakaryopoiesis is necessary for optimal platelet production and function. Megakaryopoiesis is a complex process that involves the differentiation of bipotential erythroid/megakaryocyte progenitors to megakaryocyte progenitors followed by their differentiation to megakaryocyte precursor cells. While megakaryocyte progenitors proliferate, megakaryocyte precursors lack proliferative potential, but instead replicate DNA and increase cellular content to form mature polyploid megakaryocytes that shed platelets.
Forkhead box protein 3 (Foxp3) is a key transcription factor believed to be restricted to a subset of regulatory T (T reg ) cells and is required for their development. 4, 5 Genetic mutations in Foxp3 lead to an X-linked often fatal autoimmune disease known as IPEX (immune dysregulation, polyendocrinopathy, enteropathy, x-linked) syndrome in humans. 6 A similar disease arising from a Foxp3 mutation occurs in the spontaneous mouse mutant scurfy (Foxp3 sf ) in which a frameshift mutation in Foxp3 results in a dysfunctional product lacking the forkhead domain. 7 The defects observed in IPEX and scurfy have been ascribed to dysfunctional T regs . Based on the low platelet numbers and gastrointestinal bleeding in the presence of mutant Foxp3 in Foxp3 sf mice and IPEX patients, 8, 9 we hypothesized that Foxp3 plays an intrinsic role in megakaryocyte maturation and thrombopoiesis. In this article, we report the expression of Foxp3 in human and mouse megakaryocytes, demonstrate its importance in megakaryopoiesis, and describe the platelet phenotype in Foxp3 sf mice and in a case of IPEX syndrome.
Materials and Methods

Cell Culture and Treatment Conditions
Meg-01 cells were originally established from the bone marrow of a patient with Philadelphia chromosome-positive chronic myelogenous leukemia, 10 and M07e cells, human leukemic cells with megakaryoblastic features, 11 were purchased from the American Type Culture Collection (Rockville, Md). These and Dami cells, established from the blood of a patient with megakaryoblastic leukemia, were cultured as previously described. 12 The primary human lung fibroblast strain, L828, were cultured as previously described. 13 
Megakaryocyte Differentiation From Human Cord Blood-Derived CD34؉ Cells
Human CD34ϩ cord blood cells were obtained from AllCells (Emeryville, Calif). Cells were plated at 2.5ϫ10 5 cells per well in a 12-well plate and cultured in serum-free medium as previously described 12 and supplemented with 100 ng/mL of recombinant human thrombopoietin (rhTPO; R&D Systems). After 14 days in culture, primary human megakaryocytes were identified by staining with a CD61-FITC antibody and analyzed on a BD Biosciences FACSCalibur flow cytometer. Cells were greater than 95% CD61 positive. Data were analyzed using FlowJo software (Treestar).
Quantitative Real-Time PCR Analysis
Sequences for PCR primer pairs were as follows: human Foxp3, forward 5Ј-GAAACAGCACATTCCCAGAGTTC-3Ј and reverse 5Ј-AGGTGGCAGGATGGTTTCTG-3Ј; human 7S, forward 5Ј-ACCACCAGGTTGCCTAAGGA-3Ј and reverse 5Ј-CACGGGAG TTTTGACCTGCT-3Ј. Another set of human Foxp3 primer pairs 14 were used to confirm results from primers listed above: human Foxp3, forward 5Ј-CGGACCATCTTCTGGATGAG-3Ј and reverse 5Ј-TTGTCGGATGATGCCACAG-3Ј.
Western Blot Analysis
Whole cell lysates were prepared using ELB buffer plus protease and phosphatase inhibitors as previously described. 15 One hundred micrograms of protein was electrophoresed and membranes probed with hFOXY antibody (1:500) (eBioscience). Human Foxp3 transfected cell lysate (BioLegend) was used as a positive control.
Flow Cytometric Analysis
1ϫ10
6 cells were fixed and permeabilized with Foxp3 staining buffer (eBioscience) and stained for Foxp3 using the clone PCH101 (eBioscience) or clone 236A/E7 (eBioscience) according to the manufacturer's instructions. Cells were incubated with isotype control antibodies (eBioscience) and fluorescence was analyzed as described. 12 For DNA content analysis, cells were fixed overnight in 95% ethanol at 4°C. Cells were washed and incubated with 3 mol/L of DAPI for 20 minutes at 37°C.
Immunofluorescence
Cell cytospins were mounted on slides and stained for Foxp3 intracellularly as described above. Cells were visualized using an Olympus BX51 light microscope (Olympus), photographed with a SPOT camera, and analyzed with SPOT RT software.
Animals
Blood was obtained from the orbital sinus of male B6.Cg-Foxp3 sf (Foxp3 sf ) and background strain C57BL/6J mice (Jackson Laboratories) at age 24 days. C57BL/6J, age-matched, male mice were used as a comparative control because Foxp3 sf /ϩ females were backcrossed to C57BL/6J males to maintain Foxp3 sf mice. 16 -18 Platelet counts were also performed on healthy C57BL/6J male siblings of the Foxp3 sf mice. Platelets were counted, and mean platelet volume (MPV) was determined using the Heska CBC-Diff Veterinary Analyzer. Serum was prepared by allowing whole blood clot for 30 minutes at 37°c and placing the blood on ice for 2 hours. Bone marrow was harvested from the femora of Foxp3 sf and C57BL/6J mice. 2ϫ10 4 megakaryocytes were cytospun on glass slides and stained with a Diff-Quik stain set (Dade Behring).
Analysis of Megakaryocytes in Foxp3 sf Mice
Megakaryocyte number was assessed by counting the number of megakaryocytes in 5 low power (10ϫ) fields. Megakaryocyte progenitor (Meg-CFCs) assay was performed as previously published. 19 Meg-CFCs were defined by the expression of GP1b␤ 
siRNA to Knock-Down Foxp3
Foxp3 shRNA individual clone was obtained from Open Biosystems. 1ϫ10 6 Meg-01 cells were nucleofected with 2 g of pLKO.1 HIV-based lentiviral vector expressing human shRNA Foxp3 plasmid or an empty vector plasmid using Amaxa Biosystem's Cell Line Nucleofector Kit C, program V-001. Meg-01 cells were analyzed for Foxp3 expression 24, 48, and 72 hours posttransfection by flow cytometry. Four hours after nucleofection, cells were washed and proliferation was analyzed using CellTrace CFSE (carboxyfluorescein diacetate, succinimidyl ester) according to the manufacturer's instructions (Invitrogen). Mitomycin C (Sigma), which crosslinks DNA and inhibits cell division, was used as a proliferation negative control and Meg-01 cells that were not nucleofected were used as a positive control.
Measuring TXB 2 , CD40L, TGF-␤, 12(S)-HETE, and Platelet Factor 4 (PF4)
Mouse blood was collected and anticoagulated with acid-citratedextrose (ACD) or activated with either ADP (10 mol/L) or thrombin (10 U/mL) for 30 minutes. Plasma was obtained by centrifuging anticoagulated blood at 3000 g for 10 minutes. Serum was obtained by centrifuging coagulated blood at 3000 g for 10 minutes. TXB 2 was measured using a competetive enzyme immunoassay (EIA) kit (Cayman Chemical). CD40L, TGF-␤, and platelet factor 4 (PF4) were measured using sandwich enzymelinked immunosorbent assays (ELISAs; R&D Systems). 12-hydroperoxyeicosatetraenoic acid (12(S)-HETE) was measured using an EIA (Assay Designs).
Human Serum Collection and Blood Platelet Isolation
Whole blood was obtained under University of Rochester IRB approval from male donors and an IPEX donor using Vacutainer tubes containing buffered sodium citrate or no anticoagulant for serum collection (BD Biosciences). The IPEX patient was previously revealed to have a G to A transition (1150GϾA) in exon 11, resulting in a substitution of Ala to Thr at residue 384, within the DNA binding domain of Foxp3. 20 Platelets were isolated as described. 21, 22 Complete blood counts were performed on an Abbott Cell-Dyn 1700. Platelet purity was typically greater than 99%. Plasma and serum were analyzed for human TGF-␤ and TXB 2 (Cayman Chemical). Human CD40L was analyzed by ELISA as described. 21 
Human Platelet Activation
Washed platelets were spread on fibrinogen-coated (150 g/mL) slides as described. 19 Platelet spreading is critical for platelet-surface contact during wound healing and is used as a measure of platelet function. 23 In addition, 3ϫ10 7 platelet/300 L were incubated (37°C) with platelet activators: Thrombin 0.8 U/mL (Sigma), collagen 10 g/mL (Chronolog Corporation), and adenosine diphospate (ADP) 10 mol/L (Chronolog Corporation). After treatment, platelets were centrifuged (1200g/1 minute), and supernatants were analyzed for human TGF-␤, TXB 2 , platelet factor 4 (PF4), and CD40L.
Statistical Analysis
Results are expressed as the meanϮSD. Statistical analysis was performed using a paired 2-tailed Student t test with PϽ0.05 deemed as statistically significant. All experiments were repeated at least 3 times unless otherwise stated.
Results
Megakaryocytes and Megakaryoblastic Cell Lines Express Foxp3 mRNA and Protein
To determine whether Foxp3 mRNA is expressed in megakaryocytes, real-time PCR analysis was used to evaluate 3 different megakaryocytic cell lines (Meg-01, M07e, and Dami) and primary human megakaryocytes. L828 RNA was used as a negative control as human fibroblasts were found to be negative for Foxp3 mRNA. 24 Human CD4 ϩ
CD25
ϩ T cells were isolated from peripheral blood and activated with anti-CD3 and anti-CD8 beads. 25 The RNA was isolated and used as a positive control. As shown in Figure 1 , all 3 human megakaryocyte cell lines expressed Foxp3 mRNA, as did primary human megakaryocytes. However, Foxp3 transcript levels were lower compared to activated T cells. Expression of Foxp3 mRNA was confirmed using 2 different primer sets for Foxp3.
To determine whether the expression of Foxp3 mRNA resulted in the production of Foxp3 protein, human megakaryocytes were examined by flow cytometry using intracellular staining and by Western blotting using antibodies with different specificities for Foxp3. Flow cytometric analysis using the PCH101 antibody clone, which binds the C terminus of the transcription factor, showed that all 3 4 megakaryoblastic cells were stained for Foxp3 using an intracellular staining protocol, cytospun onto slides, and cover-slipped. Foxp3 expression was analyzed by fluorescence microscopy, and photographs were taken of individual cells at 400ϫ magnification. Bar in first picture represents 10 m.
megakaryoblastic cell lines and primary human megakaryocytes expressed intracellular Foxp3 protein ( Figure 1B) . Foxp3 was not detected in human blood platelets. These results were confirmed using the 236A/E7 antibody clone, which binds to an internal portion of Foxp3 (data not shown). These data reveal that megakaryoblastic cell lines have about 2 to 4 times as much Foxp3 protein as primary human megakaryocytes.
To support the flow cytometric data, Western blotting was performed using the hFoxy antibody clone. Human Foxp3 transfected cell lysate and human PBMC lysate were used as positive controls. Figure 1B demonstrates that megakaryocytes express Foxp3 protein, yet platelets themselves lack detectable Foxp3 protein. Western blotting also confirmed that 2 to 4 times more Foxp3 protein was detected in Meg-01, M07e, and Dami cells compared to primary human megakaryocytes ( Figure 1C) .
Next, immunofluorescent staining using the PCH101 antibody was used to determine the subcellular localization of Foxp3. Figure 1D shows the presence of Foxp3 protein in 3 different megakaryoblastic cell lines and in primary human megakaryocytes, where it was predominantly detected in the nuclei ( Figure 1D ).
Foxp3 Protein Expression Is Enhanced With Phorbol Ester Myristate Acetate-Induced Megakaryocyte Maturation
Meg-01 cells and primary human megakaryocytes were treated with the megakaryocyte differentiation agent, phorbol ester myristate acetate (PMA; 50 nmol/L to 1 mol/L), for 24 hours. 
Characterization of Megakaryocytes in
Foxp3 sf Mice
In support of our human megakaryocyte data, mouse bone marrow megakaryocytes were also found to express Foxp3 protein ( Figure 3) . To determine the functional significance of megakaryocytic Foxp3, Foxp3 sf mice were studied. To assess the influence of mutant Foxp3 on platelet levels, platelet counts were performed on 4 individual Foxp3 sf and C57BL/6J mice. Wild-type, C57BL/6J, healthy siblings of the Foxp3 sf mice had platelet counts similar to the C57BL/6J mice (data not shown). Foxp3 sf mice have up to 53% fewer platelets compared to C57BL/6J mice ( Figure 3B ) and we newly report that Foxp3 sf mice have Ϸ4-fold less mature bone marrow megakaryocytes than normal mice ( Figure 3C and 3D). 
Characterization of Megakaryocyte Progenitors in
Foxp3 sf Mice
To determine whether this reduction in megakaryocyte number was attributable to a reduction in megakaryocyte progenitors, we next performed a Meg-CFC colony assay. Meg-CFC-derived colonies were identified by labeling with anti-GPIb␤ antibodies. Figure 4 demonstrates that Foxp3 sf mice have an Ϸ50% reduction in megakaryocyte progenitors compared to the C57BL/6J mice. In addition, mean colony size was lower in Foxp3 sf mice, exhibiting significantly fewer colonies in the 3 to 50 cell count range, compared to the C57BL/6J mice ( Figure 4B ). Figure 4C demonstrates that nucleofecting Meg-01 cells with a pLKO.1 lentiviral vector expressing human shRNA Foxp3 plasmid reduced Foxp3 protein to undetectable levels by 24 hours. This knockdown persisted through 72 hours (data not shown). Four hours after nucleofection, cells were washed and labeled with CFSE to measure the proliferative response of the Foxp3 knockdown. CFSE passively diffuses into cells and forms fluorescent conjugates. 26 Labeled cells are retained during meiosis, and the label is inherited by the daughter cells during cell division. 27 Fluorescence was analyzed after 72 
Meg-01 Cells Lacking Foxp3 Protein Have Reduced Proliferation
Characterization of Platelets in Foxp3 sf Mice
Impaired megakaryopoiesis can lead to platelets abnormal in size and function, so we hypothesized that Foxp3 sf mice would have platelet dysfunction in addition to thrombocytopenia. Platelet size may reflect altered function, 28 and Figure  5 demonstrates that mean platelet volumes were significantly increased in Foxp3 sf mice (nϭ4). Each group contained the same 4 animals that had platelet counts depicted in Figure 3B . As another measure of platelet function, we next measured levels of key hemostatic mediators released on platelet activation: transforming growth factor beta (TGF-␤), thromboxane B 2 (TXB 2 ), CD40 ligand (CD40L), and 12-hydroperoxyeicosatetraenoic acid 12(S)-HETE. Whereas we found no differences in plasma levels of TGF-␤, TXB 2 , CD40L, and 12(S)-HETE (data not shown), Foxp3 sf mice (nϭ6) demonstrated reduced serum levels of TGF-␤ and elevated serum levels of CD40L, TXB 2 , and 12(S)-HETE compared to C57BL/6J mice (nϭ6; Figure 5B ). These data suggest altered platelet release.
Characterization of Platelets in IPEX
IPEX is a very rare disease involving various Foxp3 mutations. 29 Platelet function has not been studied in these patients, although thrombocytopenias are reported in some cases. We obtained blood from a 17-year-old male with IPEX syndrome. He had a platelet count of 434 000/L of blood and a mean platelet volume of 10.4 fL, both at the upper end of the normal range. In addition, a subset of his platelets were unusually large (ie, 32 fL). Strikingly, the IPEX platelets exhibited prominent defects in spreading on fibrinogen (Figure 6 ) and collagen-coated slides (data not shown). Sixty percent of platelets derived from a normal donor fully spread, whereas only 5% of IPEX platelets fully spread.
IPEX platelets failed to release both TGF-␤ and CD40L after activation with either thrombin, collagen, or ADP ( Figure 6B ), whereas they exhibited no defect in thromboxane B 2 (TXB 2 ) release (data not shown). Interestingly, IPEX unstimulated platelets had approximately 6 times more platelet factor 4 (PF4) in the supernatant compared with normal unstimulated platelets. These levels were approximately doubled with activation in both IPEX and normal platelet supernatants ( Figure 6B ). No differences in serum TGF-␤ and CD40L levels were observed between the IPEX patient and an age-matched control, suggesting that multiple platelet agonists in conjunction could promote the release of TGF-␤ and CD40L (data not shown). However, the IPEX patient had plasma CD40L levels 3 times higher than the control ( Figure 6C ).
Discussion
The specificity and restriction of Foxp3 expression to a subset of T lymphocytes has provoked controversy in the scientific literature. 30 -33 However, more recent studies indicate that Foxp3 is expressed in some epithelial cells and some tumor cells. 24, 34 The abnormal platelet levels observed and the hemorrhaging that occurs in IPEX syndrome and in Foxp3 sf mice prompted us to examine Foxp3 expression in the megakaryocyte lineage and determine whether it plays a role in megakaryopoiesis and platelet production. Herein, we demonstrate that primary human megakaryocytes and megakaryoblastic cell lines express Foxp3 mRNA and protein, although to a lesser extent than in T reg cells. Consistent with its putative role as a transcription factor, Foxp3 protein expression in megakaryocytes was predominantly nuclear which may account for the failure to detect Foxp3 in human platelets ( Figure 1C) . Nuclear localization of Foxp3 may also explain increased levels of Foxp3 protein expression after PMA treatment (Figure 2) , as PMA increases cellular DNA content in megakaryocytes by inducing endomitosis. 35 We also demonstrated that Foxp3 protein expression was greater in megakaryoblastic cell lines compared to primary human megakaryocytes ( Figure 1B and 1C) . However, the reason for and the consequences of this increased expression are unknown. It has been speculated that Foxp3 plays an intrinsic role in malignant transformation and tumor survival. 24, 36 Interestingly, the Meg-01 cell line and the Dami cell line were derived from patients with megakaryoblastic leukemias that presented elevated bone marrow blast cells and thrombocytosis. 10, 37 Future studies will examine the importance of Foxp3 expression in megakaryoblastic cell lines.
Our findings indicate that Foxp3 plays an important role in megakaryopoiesis. Foxp3 sf mice, which lack the full-length functional Foxp3 protein, had 4-fold fewer bone marrow megakaryocytes compared to C57BL/6J mice ( Figure 3D) . Further, megakaryocyte colony number was Ϸ50% lower in Foxp3 sf mice compared with C57BL/6J mice ( Figure 4A ). In addition, megakaryocyte mean colony size was lower in Foxp3 sf mice compared with that in C57BL/6J suggesting that a reduction in progenitor proliferation contributes to reduced progenitor number ( Figure 4B) . These new findings demonstrate that the reduced colony number in Foxp3 sf mice is attributable to a defect in megakaryocyte progenitor proliferation and could also be attributable to a potential role of Foxp3 in the generation of megakaryocyte progenitors from upstream bipotential or multipotential progenitors. We also observed that platelet count does not necessarily correlate with megakaryocyte number or megakaryocyte progenitor number. The platelet counts from individual mice exhibited more variability, which may indicate differences in the ability of mature megakaryocytes to produce platelets. These data, however, do not rule out the possibility that the reduced megakaryocyte number is a consequence of profound defects in T regulatory cells. Megakaryopoiesis may be impaired in vivo because of the wide range of autoimmune-associated symptoms which characterize the Foxp3 sf mouse. However, Foxp3 knockdown human Meg-01 cells demonstrate a greatly reduced proliferative response, suggesting a direct role for Foxp3 in megakaryopoiesis ( Figure 4D ).
The precise mechanism by which Foxp3 regulates megakaryopoiesis remains unknown. Foxp3 functions in T lymphocytes, in part, as a transcriptional repressor by recruiting both histone acetyl transferases and histone deacetylases. 38 Foxp3 also functions as a passive transcriptional repressor by physically interacting with proteins such as nuclear factor-kappa B (NF-B) 39, 40 and acute myeloid leukemia 1 (Aml1)/runt-related transcription factor 1 (Runx1). 41 Foxp3 may be playing a similar role in megakaryocytes by suppressing or activating transcription factors.
Genetic lesions in megakaryocytes that cause thrombocytopenia often cause abnormal platelet function. Foxp3 sf mice have reduced platelet counts and our new findings demonstrate that they exhibit striking activation abnormalities. TGF-␤ serum levels were significantly lower in Foxp3 sf mice. Because platelet-derived TGF-␤ is a cytokine mainly involved in wound healing and tissue repair, we speculate that reduced TGF-␤ could potentiate the dermatitis and the skin lesions which characterize the IPEX disease and the Foxp3 sf mice. In addition, TGF-␤ can suppress T cell responses. TGF-␤ reduces T cell proliferation by inhibiting IL-2 production and upregulating cell cycle inhibitors 42 and inhibits the differentiation of Th1 to Th2 by downregulating T-bet and GATA-3. 43 TGF-␤ also inhibits the activation of macrophages and reduces the ability of dendritic cells to present antigens to T cells. 42 Interestingly, we found that Foxp3 sf serum had elevated levels of CD40L and 2 arachidonic acid metabolites, TXB 2 and 12(S)-HETE, despite having fewer platelets. TXB 2 is a more stable metabolite of thromboxane A 2 (TXA 2 ), a cyclooxygenase-derived product generated by platelets which induces irreversible platelet aggregation and vascular smooth muscle contraction. 12(S)-HETE is a 12-lipoxygenase-derived product that is produced abundantly in platelets during activation. These data suggest that the Foxp3 sf platelets produce more arachidonic acid metabolites during activation. As described in the Introduction, CD40L activates immune and structural cells, as well as platelets. The majority of the circulating soluble CD40L originates from A, Left picture shows microscopy of normal platelets spread on a fibrinogencoated slide. Right picture shows microscopy of platelets derived from an IPEX patient spread on a fibrinogen coated slide. Bar graph demonstrates the number of platelets of a total 125 platelets that were either fully spread, partially spread, or not spread. Platelets were counted from several 100ϫ fields. B, IPEX donor insufficiently released CD40L and TGF-␤ in response to thrombin, collagen, or ADP. IPEX donor exhibited higher levels (6ϫ) of PF4 in the supernatants from both unactivated and activated platelets. C, IPEX donor exhibited 3ϫ higher plasma levels of CD40L when compared to an age-matched male control. platelets and CD40L levels are elevated during inflammatory disease states. 44 -46 Collectively, these new data suggest that the platelet phenotype in Foxp3 sf mice contributes to the inflammation observed in the 'scurfy' disease. Foxp3 sf mice also had increased mean platelet volumes ( Figure 5A ). There are many intrinsic and reactive reasons why platelet volume is elevated in disease states. For example, Gata-1 knockout mice have deficiencies in megakaryocyte maturation, and as a result their platelets have elevated volumes. 47 The peripheral platelet destruction from circulating antiplatelet antibodies increases platelet volume in immune thrombocytopenic purpura (ITP) patients because a higher percentage of platelets are younger. 48, 49 Therefore, the increased platelet size observed in Foxp3 sf mice may indicate both impaired platelet production and peripheral platelet destruction or in contrast that the elevated mean platelet volume may be compensating for the decrease in platelet number.
To determine whether a similar platelet phenotype was observed in IPEX, the human correlate of scurfy, we examined the platelets of an IPEX patient. IPEX is rare disease involving various Foxp3 mutations and can result in death at an early age. 29 About 50% of IPEX patients are reported to be thrombocytopenic, and hemorrhage is one of the most common causes of death in untreated patients. 9 Gastrointestinal bleeding has occurred in a case with normal platelet counts, suggesting inadequate platelet function. 50 The IPEX donor evaluated herein was aged 17 years and had a G to A transition (1150GϾA) in exon 11, resulting in a substitution of Ala to Thr at residue 384, within the DNA-binding domain of Foxp3. 20 His platelets demonstrated striking abnormalities in spreading ( Figure 6A ) and a reduced ability to release CD40L and TGF-␤ in response to potent platelet activators ( Figure 6B) . Our IPEX donor also demonstrated a profound elevation in plasma levels of CD40L ( Figure 6C ). These data indicate that the IPEX patient did not respond normally to platelet activators and possibly that his platelets already released internal stores of CD40L in vivo.
We also demonstrated that the IPEX patient had 6 times more platelet factor 4 (PF4) in the supernatants of both unactivated and activated platelets compared with the normal donor. This suggests that the IPEX platelets contain higher levels of PF4 or that the release of PF4 from alpha granules is enhanced. Because IPEX platelets release less TGF-␤ and CD40L than the normal platelets, we speculate that IPEX platelets contain higher levels of PF4. The increased release of PF4 may implicate platelets in the symptomology of IPEX. IPEX disease is characterized by severe atopic dermatitis, and recently plasma levels of PF4 were shown to be elevated in patients with atopic dermatitis and in a mouse model of atopic dermatitits. [51] [52] [53] In addition, PF4 is a negative regulator of megakaryopoiesis, suggesting that elevated PF4 may be a mechanism for inhibiting megakaryocyte proliferation. 54 Collectively, these new findings demonstrate that the defect in Foxp3 observed in IPEX influences platelet function.
Our study adds considerable new information to the ongoing discussion of the presence of Foxp3 in cell types other than T regs . Overall, we have shown that Foxp3 deficiency results in a lesion of megakaryocyte proliferation that is associated with platelet dysfunction. These new findings support the concept that genetic disorders that cause thrombocytopenia also cause abnormal platelet function such as occurs in myelodysplasias. Therefore, we have elucidated an underlying mechanism of megakaryopoiesis that contributes to the pathophysiology of IPEX syndrome and the 'scurfy' disease.
